Chemkart India Limited is a **BSE-listed (July 2025)** digital-first enterprise specializing in the **B2B supply, trading, and distribution** of nutraceutical raw materials, amino acids, and functional ingredients. The company is currently executing a high-stakes transition from a pure distribution model to a **vertically integrated platform** encompassing raw material sourcing, in-house processing, and finished formulation manufacturing. --- ### **Core Business Model & Market Presence** Chemkart serves a robust network of **500+ trusted clients** across the nutritional, sports, and health supplement industries in India. The business is characterized by a **scalable distribution model** underpinned by technology-driven inventory forecasting and a global sourcing network. * **Product Portfolio:** The company manages **10+ product categories** and **150+ ingredients**, focusing on high-purity nutritional supplements and chemical compounds. * **Digital Strategy:** Chemkart leverages **online B2B platforms** and social media (Facebook, Instagram, YouTube) for nationwide lead generation and brand visibility, distinguishing it from traditional chemical distributors. * **Quality & Compliance:** Operations are governed by international standards, including **ISO 9001:2015, ISO 22000:2018, FSSAI, Halal, and Kosher** certifications. * **Infrastructure:** The company maintains a **30,000 Sq. ft.** warehouse and internal processing capabilities, including **Grinding (1.8 MT/Day)** and **Blending (1.5 MT/Day)**, supported by a workforce of **50+ employees**. --- ### **Specialized Product Portfolio & Applications** The company’s revenue is driven by essential amino acids and performance nutrition ingredients catering to global health and industrial sectors. | Product Category | Key Offerings | Primary Applications | | :--- | :--- | :--- | | **Nutraceuticals** | **Creatine Monohydrate**, **BCAA**, **Whey Protein Concentrate 80%** | Sports nutrition, muscle recovery, and dietary supplements. | | **Specialty Chemicals** | **Glycine**, **Inositol**, **Taurine** | Pharma intermediates, food additives, and animal feed. | | **Antioxidants** | **L-Glutathione (Reduced)**, **N-Acetyl L-Cysteine (NAC)** | Wellness, skin health, and cellular protection. | | **Amino Acids** | **L-Glutamine**, **L-Carnitine**, **L-Lysine HCL** | General health, metabolic support, and clinical nutrition. | --- ### **Strategic Transformation: The CDMO & Export Pivot** Chemkart is aggressively transitioning into a **Contract Development and Manufacturing Organization (CDMO)**. This shift is centered on the development of a next-generation manufacturing facility through its wholly-owned subsidiary, **Easy Raw Materials Private Limited (EZRM)**. #### **The EZRM Greenfield Project (JNPA SEZ)** * **Location Advantage:** Situated on a **4,120 sq.m** plot at the **JNPA Special Economic Zone (SEZ)**, Navi Mumbai. Proximity to India’s largest container port provides **duty-free import-export benefits**. * **Capabilities:** The facility will produce **tablets, capsules, jars, and sachets** using advanced technologies like **microencapsulation** and **liposomal delivery systems** to enhance bioavailability. * **Timeline:** Civil and structural works are scheduled through **Q4 FY 2025-26**, with mechanical installation in **early FY 2026-27** and full operations expected in **FY27**. * **Vertical Integration:** This facility allows Chemkart to move from raw ingredient supply to providing **private label solutions** and **end-to-end export documentation** for global brands. #### **Subsidiary Ecosystem** * **Vinstar Biotech Pvt Ltd (VBPL):** Focuses on **R&D**, custom formulation, and science-led platforms for biotech, pharma, and personal care. * **Capital Allocation:** Since the IPO, Chemkart has funneled **Rs. 6.48 Crores** into EZRM through four successive rights issues (August 2025 – March 2026) to accelerate construction. --- ### **Financial Performance & IPO Capital Structure** Chemkart listed on the **BSE SME Platform** on **July 10, 2025**, raising **₹80.08 Crore**. **IPO Details & Net Worth:** * **Fresh Issue:** **2,600,000 shares** at **₹248** (**₹64.48 Cr**). * **Offer for Sale (OFS):** **629,200 shares** at **₹248** (**₹15.60 Cr**). * **Post-IPO Net Worth (Sept 30, 2025):** **₹12,022.41 Lakhs**. * **Utilization Note:** A monitoring report indicated a **60.26% excess utilization** of funds toward **General Corporate Purposes (GCP)** relative to the original prospectus. **Historical Growth (3-Year CAGR):** * **Revenue:** **32.7%** | **EBITDA:** **64.2%** | **PAT:** **67.1%** * **FY25 ROE:** **46%** | **FY25 ROCE:** **49%** **H1 FY2025-26 Headwinds:** The company is currently navigating a period of **lower realizations** due to industry-wide pricing corrections. * **Pricing Pressure:** A volume increase of **175 MT** in **Creatine Monohydrate** was offset by falling market prices. * **Volume Declines:** **Glycine** volumes dropped by **522 MT** (May–Sept 2025) due to **U.S. tariff measures** affecting a major client. * **Recovery:** Management reports a resumption of Glycine business as of **October 2025** with a **strong H2 order book**. --- ### **Risk Factors & Regulatory Challenges** Investors should note significant **regulatory and legal risks** currently impacting the company. * **DRI Investigation:** The **Directorate of Revenue Intelligence (DRI)** is investigating the **classification and valuation** of specific chemical imports (BCAA, L-Leucine, L-Isoleucine, and Valine) over a **five-year period**. * **Key Personnel Risk:** Chairman and MD, **Mr. Ankit Mehta**, was issued an **Arrest Memo** on **11 December 2025** and released on **bail** on **15 December 2025**. * **Revenue Exposure:** The company emphasizes that the products under investigation contribute only **~2.8%** (range of **1.8% to 5.3%**) of total turnover, suggesting limited financial contagion. * **Governance Response:** Chemkart has initiated proactive investor outreach to address concerns regarding **corporate governance** and maintains that operations continue **without material disruption**. --- ### **Investment Thesis Summary** Chemkart presents a high-growth opportunity tied to the **"China Plus One"** strategy and the **"Make in India"** initiative. While the company boasts exceptional historical profitability and a clear path toward high-margin manufacturing via the **JNPA SEZ facility**, the short-term outlook is clouded by **regulatory scrutiny (DRI)** and **pricing volatility** in the global chemical markets. The successful commissioning of the **EZRM facility in FY27** remains the primary catalyst for long-term value creation.